CA2757659A1 - Biomarkers for monitoring treatment of neuropsychiatric diseases - Google Patents

Biomarkers for monitoring treatment of neuropsychiatric diseases Download PDF

Info

Publication number: CA2757659A1
Authority: CA; Canada
Prior art keywords: subject; diagnostic; vagus nerve; nerve stimulation; score
Prior art date: 2009-04-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2757659A

Other languages

English (en)

French (fr)

Inventor

Bo Pi

John Bilello

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ridge Diagnostics Inc

Original Assignee

Ridge Diagnostics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-06

Filing date

2010-04-06

Publication date

2010-10-14

2010-04-06 Application filed by Ridge Diagnostics Inc filed Critical Ridge Diagnostics Inc

2010-10-14 Publication of CA2757659A1 publication Critical patent/CA2757659A1/en

Status Abandoned legal-status Critical Current

Links

239000000090 biomarker Substances 0.000 title claims abstract description 133
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 100
201000010099 disease Diseases 0.000 title claims abstract description 94
238000011282 treatment Methods 0.000 title claims abstract description 85
238000012544 monitoring process Methods 0.000 title claims abstract description 13
238000000034 method Methods 0.000 claims abstract description 98
210000001186 vagus nerve Anatomy 0.000 claims abstract description 43
230000007383 nerve stimulation Effects 0.000 claims abstract description 40
230000004044 response Effects 0.000 claims abstract description 27
208000024714 major depressive disease Diseases 0.000 claims description 60
239000012472 biological sample Substances 0.000 claims description 53
238000002560 therapeutic procedure Methods 0.000 claims description 35
230000014509 gene expression Effects 0.000 claims description 31
230000002503 metabolic effect Effects 0.000 claims description 31
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 claims description 28
230000002757 inflammatory effect Effects 0.000 claims description 20
210000002966 serum Anatomy 0.000 claims description 16
230000001225 therapeutic effect Effects 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 14
230000008859 change Effects 0.000 claims description 13
230000000508 neurotrophic effect Effects 0.000 claims description 13
238000005516 engineering process Methods 0.000 claims description 12
210000002381 plasma Anatomy 0.000 claims description 9
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
230000003542 behavioural effect Effects 0.000 claims description 6
238000009225 cognitive behavioral therapy Methods 0.000 claims description 6
238000003384 imaging method Methods 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 5
239000008280 blood Substances 0.000 claims description 5
238000002651 drug therapy Methods 0.000 claims description 4
210000004698 lymphocyte Anatomy 0.000 claims description 4
238000001671 psychotherapy Methods 0.000 claims description 4
230000003252 repetitive effect Effects 0.000 claims description 4
230000003285 pharmacodynamic effect Effects 0.000 abstract description 19
239000000463 material Substances 0.000 abstract description 11
108090000623 proteins and genes Proteins 0.000 description 21
206010061218 Inflammation Diseases 0.000 description 20
230000004054 inflammatory process Effects 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 17
239000012491 analyte Substances 0.000 description 14
230000000638 stimulation Effects 0.000 description 14
208000020401 Depressive disease Diseases 0.000 description 13
238000004422 calculation algorithm Methods 0.000 description 13
238000005259 measurement Methods 0.000 description 12
230000015654 memory Effects 0.000 description 12
238000011160 research Methods 0.000 description 11
239000013598 vector Substances 0.000 description 11
108010025020 Nerve Growth Factor Proteins 0.000 description 9
102000007072 Nerve Growth Factors Human genes 0.000 description 9
239000000523 sample Substances 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
238000003556 assay Methods 0.000 description 8
238000004590 computer program Methods 0.000 description 8
239000003814 drug Substances 0.000 description 8
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
230000008569 process Effects 0.000 description 8
239000000935 antidepressant agent Substances 0.000 description 7
239000003900 neurotrophic factor Substances 0.000 description 7
229940005513 antidepressants Drugs 0.000 description 6
238000003745 diagnosis Methods 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
230000003993 interaction Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 5
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 5
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 5
238000004891 communication Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
238000004949 mass spectrometry Methods 0.000 description 5
238000012797 qualification Methods 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000011269 treatment regimen Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000003946 Prolactin Human genes 0.000 description 4
108010057464 Prolactin Proteins 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
229960000890 hydrocortisone Drugs 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
238000002493 microarray Methods 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000011002 quantification Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000004885 tandem mass spectrometry Methods 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
108010074051 C-Reactive Protein Proteins 0.000 description 3
102100032752 C-reactive protein Human genes 0.000 description 3
102400000739 Corticotropin Human genes 0.000 description 3
101800000414 Corticotropin Proteins 0.000 description 3
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 3
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 3
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
102100029268 Neurotrophin-3 Human genes 0.000 description 3
102100024735 Resistin Human genes 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000001430 anti-depressive effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
229940041967 corticotropin-releasing hormone Drugs 0.000 description 3
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000005556 hormone Substances 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
238000007477 logistic regression Methods 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
229940097325 prolactin Drugs 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
101710155856 C-C motif chemokine 3 Proteins 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
102000000013 Chemokine CCL3 Human genes 0.000 description 2
108010055166 Chemokine CCL5 Proteins 0.000 description 2
102400001368 Epidermal growth factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
108091061482 Glial cell line-derived neurotrophic factor family Proteins 0.000 description 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
102000003814 Interleukin-10 Human genes 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
102000003810 Interleukin-18 Human genes 0.000 description 2
108090000171 Interleukin-18 Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108090000742 Neurotrophin 3 Proteins 0.000 description 2
101800000933 Non-structural protein 10 Proteins 0.000 description 2
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
108010047909 Resistin Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
230000006399 behavior Effects 0.000 description 2
150000003943 catecholamines Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
229940076144 interleukin-10 Drugs 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000007620 mathematical function Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000036651 mood Effects 0.000 description 2
230000001414 neuropoietic effect Effects 0.000 description 2
229940032018 neurotrophin 3 Drugs 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
238000005457 optimization Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000000575 proteomic method Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
238000010972 statistical evaluation Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
101150028074 2 gene Proteins 0.000 description 1
101150090724 3 gene Proteins 0.000 description 1
101150033839 4 gene Proteins 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
102400000630 Acylation stimulating protein Human genes 0.000 description 1
101800000415 Acylation stimulating protein Proteins 0.000 description 1
102000011690 Adiponectin Human genes 0.000 description 1
108010076365 Adiponectin Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010002869 Anxiety symptoms Diseases 0.000 description 1
102000030169 Apolipoprotein C-III Human genes 0.000 description 1
108010056301 Apolipoprotein C-III Proteins 0.000 description 1
102400000059 Arg-vasopressin Human genes 0.000 description 1
101800001144 Arg-vasopressin Proteins 0.000 description 1
102100026376 Artemin Human genes 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
108010029697 CD40 Ligand Proteins 0.000 description 1
102100032937 CD40 ligand Human genes 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
206010054089 Depressive symptom Diseases 0.000 description 1
102000030914 Fatty Acid-Binding Human genes 0.000 description 1
101100226596 Gallus gallus FABP gene Proteins 0.000 description 1
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
101000785776 Homo sapiens Artemin Proteins 0.000 description 1
101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 description 1
101000686909 Homo sapiens Resistin Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102400000569 Myeloperoxidase Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010061952 Orosomucoid Proteins 0.000 description 1
102000012404 Orosomucoid Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
108010026552 Proteome Proteins 0.000 description 1
238000011529 RT qPCR Methods 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102000043322 Reelin Human genes 0.000 description 1
108700038365 Reelin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 1
102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 1
101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
108700028909 Serum Amyloid A Proteins 0.000 description 1
102000054727 Serum Amyloid A Human genes 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000008238 biochemical pathway Effects 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
238000007622 bioinformatic analysis Methods 0.000 description 1
230000008236 biological pathway Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
230000001612 cachectic effect Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000012085 chronic inflammatory response Effects 0.000 description 1
230000037326 chronic stress Effects 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
238000013500 data storage Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000000104 diagnostic biomarker Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
238000004146 energy storage Methods 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
108091022862 fatty acid binding Proteins 0.000 description 1
230000009123 feedback regulation Effects 0.000 description 1
239000010408 film Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
238000011331 genomic analysis Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
238000001871 ion mobility spectroscopy Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
238000013332 literature search Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
201000003995 melancholia Diseases 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
210000000607 neurosecretory system Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000000053 physical method Methods 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
102220300875 rs1554026816 Human genes 0.000 description 1
102220212642 rs747431847 Human genes 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
-1 serum amyloid P Proteins 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
238000013517 stratification Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
102000015534 trkB Receptor Human genes 0.000 description 1
108010064880 trkB Receptor Proteins 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Spectroscopy & Molecular Physics (AREA)
Medical Informatics (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Signal Processing (AREA)
Immunology (AREA)
Software Systems (AREA)
Evolutionary Biology (AREA)
Bioethics (AREA)
Theoretical Computer Science (AREA)
Public Health (AREA)
Pathology (AREA)
Evolutionary Computation (AREA)
Epidemiology (AREA)
Bioinformatics & Computational Biology (AREA)
Microbiology (AREA)
Artificial Intelligence (AREA)
Databases & Information Systems (AREA)
Data Mining & Analysis (AREA)
Computer Vision & Pattern Recognition (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2757659A 2009-04-06 2010-04-06 Biomarkers for monitoring treatment of neuropsychiatric diseases Abandoned CA2757659A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16698609P	2009-04-06	2009-04-06
US61/166,986		2009-04-06
PCT/US2010/030104 WO2010118035A2 (en)	2009-04-06	2010-04-06	Biomarkers for monitoring treatment of neuropsychiatric diseases

Publications (1)

Publication Number	Publication Date
CA2757659A1 true CA2757659A1 (en)	2010-10-14

Family

ID=42936849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2757659A Abandoned CA2757659A1 (en)	2009-04-06	2010-04-06	Biomarkers for monitoring treatment of neuropsychiatric diseases

Country Status (6)

Country	Link
US (1)	US20100280562A1 (2)
EP (1)	EP2417448A4 (2)
JP (1)	JP2012523009A (2)
CN (1)	CN102460153A (2)
CA (1)	CA2757659A1 (2)
WO (1)	WO2010118035A2 (2)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10912712B2 (en)	2004-03-25	2021-02-09	The Feinstein Institutes For Medical Research	Treatment of bleeding by non-invasive stimulation
US8868177B2 (en) *	2009-03-20	2014-10-21	ElectroCore, LLC	Non-invasive treatment of neurodegenerative diseases
US8158374B1 (en)	2006-09-05	2012-04-17	Ridge Diagnostics, Inc.	Quantitative diagnostic methods using multiple parameters
US9662490B2 (en)	2008-03-31	2017-05-30	The Feinstein Institute For Medical Research	Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
EP2337866B1 (en) *	2008-10-15	2014-07-30	Ridge Diagnostics, Inc.	Human biomarker hypermapping for depressive disorders
WO2010059709A2 (en)	2008-11-18	2010-05-27	Ridge Diagnostics, Inc.	Metabolic syndrome and hpa axis biomarkers for major depressive disorder
CA2757518A1 (en) *	2009-04-01	2010-10-07	Ridge Diagnostics, Inc.	Biomarkers for monitoring treatment of neuropsychiatric diseases
US9211410B2 (en)	2009-05-01	2015-12-15	Setpoint Medical Corporation	Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh)	2009-06-09	2016-01-20	赛博恩特医疗器械公司	用于无导线刺激器的具有袋部的神经封套
US11051744B2 (en)	2009-11-17	2021-07-06	Setpoint Medical Corporation	Closed-loop vagus nerve stimulation
CN102821814B (zh)	2009-12-23	2015-07-15	赛博恩特医疗器械公司	用于治疗慢性炎症的神经刺激设备和系统
WO2011094308A2 (en) *	2010-01-26	2011-08-04	Ridge Diagnostics, Inc.	Multiple biomarker panels to stratify disease severity and monitor treatment of depression
JP6074846B2 (ja)	2010-12-16	2017-02-08	国立研究開発法人産業技術総合研究所	髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
US20120238837A1 (en) *	2011-03-16	2012-09-20	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions
US12172017B2 (en)	2011-05-09	2024-12-24	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en)	2012-03-26	2017-02-21	Setpoint Medical Corporation	Devices and methods for modulation of bone erosion
US8737709B2 (en) *	2012-04-30	2014-05-27	General Electric Company	Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
CA3112130A1 (en)	2013-07-11	2015-01-15	University Of North Texas Health Science Center At Fort Worth	Blood-based screen for detecting neurological diseases in primary care settings
AU2014354808A1 (en) *	2013-11-26	2016-06-02	University Of North Texas Health Science Center At Fort Worth	Personalized medicine approach for treating cognitive loss
WO2015127476A1 (en) *	2014-02-24	2015-08-27	Setpoint Medial Corporation	Vagus nerve stimulation screening test
WO2016004375A2 (en) *	2014-07-02	2016-01-07	Ridge Diagnostics, Inc.	Methods and materials for treating pain and depression
US11154712B2 (en) *	2014-08-28	2021-10-26	Medtronic Ardian Luxembourg S.A.R.L.	Methods for assessing efficacy of renal neuromodulation and associated systems and devices
US11311725B2 (en)	2014-10-24	2022-04-26	Setpoint Medical Corporation	Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en)	2015-02-03	2016-08-11	Setpoint Medical Corporation	Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en)	2016-01-13	2020-03-24	Setpoint Medical Corporation	Systems and methods for establishing a nerve block
EP3405255B1 (en)	2016-01-20	2025-12-31	Setpoint Medical Corporation	IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US11471681B2 (en)	2016-01-20	2022-10-18	Setpoint Medical Corporation	Batteryless implantable microstimulators
EP3405107B1 (en)	2016-01-20	2023-04-12	Setpoint Medical Corporation	Control of vagal stimulation
US10583304B2 (en)	2016-01-25	2020-03-10	Setpoint Medical Corporation	Implantable neurostimulator having power control and thermal regulation and methods of use
WO2018077844A1 (en)	2016-10-28	2018-05-03	Telefonica Innovacion Alpha S.L.	System and a method for enabling responsive cognitive behavioral therapy
WO2018195238A1 (en) *	2017-04-20	2018-10-25	The Feinstein Institute For Medical Research	Systems and methods for real-time monitoring of physiological biomarkers through nerve signals and uses thereof
WO2019036470A1 (en) *	2017-08-14	2019-02-21	Setpoint Medical Corporation	TESTING TEST FOR STIMULATION OF NERVE WAVE
CN111148844A (zh)	2017-09-01	2020-05-12	韦恩生物科技股份公司	鉴定和使用糖肽作为诊断和治疗监测的生物标记物
WO2019143562A1 (en) *	2018-01-18	2019-07-25	University Of North Texas Health Science Center At Fort Worth	Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
US11260229B2 (en)	2018-09-25	2022-03-01	The Feinstein Institutes For Medical Research	Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en)	2019-04-12	2025-11-20	Setpoint Medical Corporation	Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja)	2020-01-13	2023-03-27	ザファインスタインインスティチューツフォーメディカルリサーチ	脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
CN111524596A (zh) *	2020-04-07	2020-08-11	上海市精神卫生中心（上海市心理咨询培训中心）	一种判断青少年双相障碍发病风险的方法
WO2021236977A1 (en)	2020-05-21	2021-11-25	The Feinstein Institutes For Medical Research	Systems and methods for vagus nerve stimulation
WO2022245878A1 (en)	2021-05-17	2022-11-24	Setpoint Medical Corporation	Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en)	2022-01-20	2025-07-17	Setpoint Medical Corporation	Treatment of inflammatory disorders

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5359681A (en) *	1993-01-11	1994-10-25	University Of Washington	Fiber optic sensor and methods and apparatus relating thereto
US5882203A (en) *	1995-05-31	1999-03-16	Correa; Elsa I.	Method of detecting depression
US5658802A (en) *	1995-09-07	1997-08-19	Microfab Technologies, Inc.	Method and apparatus for making miniaturized diagnostic arrays
US5804453A (en) *	1996-02-09	1998-09-08	Duan-Jun Chen	Fiber optic direct-sensing bioprobe using a phase-tracking approach
US20050123938A1 (en) *	1999-01-06	2005-06-09	Chondrogene Limited	Method for the detection of osteoarthritis related gene transcripts in blood
US20030032200A1 (en) *	2000-02-24	2003-02-13	Herath Herath Mudiyanselage Athula Chandrasiri	Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression
US20040110938A1 (en) *	2000-02-24	2004-06-10	Parekh Rajesh Bhikhu	Proteins, genes and their use for diagnosis and treatment of schizophrenia
KR100776980B1 (ko) *	2000-03-09	2007-11-21	클리니컬 어낼리시스 코포레이션	의료진단시스템
US7118710B2 (en) *	2000-10-30	2006-10-10	Sru Biosystems, Inc.	Label-free high-throughput optical technique for detecting biomolecular interactions
US6905816B2 (en) *	2000-11-27	2005-06-14	Intelligent Medical Devices, Inc.	Clinically intelligent diagnostic devices and methods
EP1322957B1 (en) *	2001-05-04	2009-08-12	Biosite Incorporated	Diagnostic markers of acute coronary syndromes and methods of use thereof
US6710877B2 (en) *	2001-07-23	2004-03-23	Corning Incorporated	Apparatus and methods for determining biomolecular interactions
US20050095646A1 (en) *	2001-11-19	2005-05-05	Sherman Michael I.	Method of using a non-antibody protein to detect and measure an analyte
US7136518B2 (en) *	2003-04-18	2006-11-14	Medispectra, Inc.	Methods and apparatus for displaying diagnostic data
US20040152107A1 (en) *	2002-09-18	2004-08-05	C. Anthony Altar	Gene signature of electroshock therapy and methods of use
KR20040032451A (ko) *	2002-10-09	2004-04-17	삼성전자주식회사	생체신호 기반의 건강 관리 기능을 갖는 모바일 기기 및이를 이용한 건강 관리 방법
US7490085B2 (en) *	2002-12-18	2009-02-10	Ge Medical Systems Global Technology Company, Llc	Computer-assisted data processing system and method incorporating automated learning
US7418290B2 (en) *	2003-05-06	2008-08-26	Aspect Medical Systems, Inc.	System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram
US7706871B2 (en) *	2003-05-06	2010-04-27	Nellcor Puritan Bennett Llc	System and method of prediction of response to neurological treatment using the electroencephalogram
US20040228765A1 (en) *	2003-05-14	2004-11-18	Witty Thomas R.	Point of care diagnostic platform
US20040228766A1 (en) *	2003-05-14	2004-11-18	Witty Thomas R.	Point of care diagnostic platform
US20050084880A1 (en) *	2003-07-11	2005-04-21	Ronald Duman	Systems and methods for diagnosing & treating psychological and behavioral conditions
US20070092888A1 (en) *	2003-09-23	2007-04-26	Cornelius Diamond	Diagnostic markers of hypertension and methods of use thereof
US20050069936A1 (en) *	2003-09-26	2005-03-31	Cornelius Diamond	Diagnostic markers of depression treatment and methods of use thereof
US7394547B2 (en) *	2003-11-06	2008-07-01	Fortebio, Inc.	Fiber-optic assay apparatus based on phase-shift interferometry
JP2005312435A (ja) *	2004-03-29	2005-11-10	Kazuhito Rokutan	うつ病の評価方法
US20050254065A1 (en) *	2004-05-12	2005-11-17	Stokowski Stanley E	Method and apparatus for detecting surface characteristics on a mask blank
AU2005257705A1 (en) *	2004-06-24	2006-01-05	Ge Healthcare Bio-Sciences Ab	Method for detecting molecular surface interactions
US20060063199A1 (en) *	2004-09-21	2006-03-23	Elgebaly Salwa A	Diagnostic marker
US7445887B2 (en) *	2005-01-07	2008-11-04	Fortebio, Inc.	Enzyme activity measurements using bio-layer interferometry
JP2007024822A (ja) *	2005-07-21	2007-02-01	Aska Pharmaceutical Co Ltd	男性の更年期又はうつ病の鑑別方法
EP1949123A2 (en) *	2005-10-18	2008-07-30	Cambridge Enterprise Limited	Methods and biomarkers for diagnosing and monitoring psychotic disorders
US20070161042A1 (en) *	2006-01-11	2007-07-12	Fortebio, Inc.	Methods for characterizing molecular interactions
WO2007094472A1 (ja) *	2006-02-17	2007-08-23	Atsuo Sekiyama	生体負荷の指標剤および生体負荷の測定方法
US20080015465A1 (en) *	2006-06-15	2008-01-17	Scuderi Gaetano J	Methods for diagnosing and treating pain in the spinal cord
US7651836B2 (en) *	2006-08-04	2010-01-26	Hospital Santiago Apóstol	Methods for diagnosis and prognostic of psychiatric diseases
US8158374B1 (en) *	2006-09-05	2012-04-17	Ridge Diagnostics, Inc.	Quantitative diagnostic methods using multiple parameters
US20080199866A1 (en) *	2006-10-10	2008-08-21	The Board Of Trustees Of The Leland Stanford Junior University	Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
WO2008099972A1 (ja) *	2007-02-16	2008-08-21	Shimadzu Corporation	上皮性卵巣癌の組織型識別マーカー、及びそれを用いた組織型に基づく上皮性卵巣癌の罹患の識別法
US20080281531A1 (en) *	2007-03-15	2008-11-13	Kazuhito Rokutan	Method for Diagnosing Depression
CN102037355A (zh) *	2008-03-04	2011-04-27	里奇诊断学股份有限公司	基于多重生物标记物板块诊断和监测抑郁症
EP2272044A4 (en) *	2008-03-12	2011-07-06	Ridge Diagnostics Inc	INFLAMMATORY BIOMARKING FOR MONITORING DEPRESSION DISEASES
EP2337866B1 (en) *	2008-10-15	2014-07-30	Ridge Diagnostics, Inc.	Human biomarker hypermapping for depressive disorders
WO2010059709A2 (en) *	2008-11-18	2010-05-27	Ridge Diagnostics, Inc.	Metabolic syndrome and hpa axis biomarkers for major depressive disorder
CA2757518A1 (en) *	2009-04-01	2010-10-07	Ridge Diagnostics, Inc.	Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2011094308A2 (en) *	2010-01-26	2011-08-04	Ridge Diagnostics, Inc.	Multiple biomarker panels to stratify disease severity and monitor treatment of depression
JP2014500503A (ja) *	2010-12-06	2014-01-09	リッジダイアグノスティックス，インコーポレイテッド	精神神経疾患の処置をモニタリングするためのバイオマーカー

2010
- 2010-04-06 CN CN2010800258668A patent/CN102460153A/zh active Pending
- 2010-04-06 JP JP2012504782A patent/JP2012523009A/ja active Pending
- 2010-04-06 EP EP10762304A patent/EP2417448A4/en not_active Withdrawn
- 2010-04-06 US US12/754,770 patent/US20100280562A1/en not_active Abandoned
- 2010-04-06 CA CA2757659A patent/CA2757659A1/en not_active Abandoned
- 2010-04-06 WO PCT/US2010/030104 patent/WO2010118035A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2010118035A2 (en)	2010-10-14
CN102460153A (zh)	2012-05-16
WO2010118035A3 (en)	2011-01-13
JP2012523009A (ja)	2012-09-27
EP2417448A4 (en)	2012-10-24
EP2417448A2 (en)	2012-02-15
US20100280562A1 (en)	2010-11-04

Legal Events

Date	Code	Title	Description
2015-04-21	EEER	Examination request	Effective date: 20150407
2017-05-18	FZDE	Discontinued	Effective date: 20170406

Publication	Publication Date	Title
US20100280562A1 (en)	2010-11-04	Biomarkers for monitoring treatment of neuropsychiatric diseases
EP2414824B1 (en)	2017-12-06	Biomarkers for monitoring treatment of neuropsychiatric diseases
JP5744063B2 (ja)	2015-07-01	うつ病の疾患重症度を層別化するためおよび処置をモニタリングするための複数のバイオマーカーパネル
JP5663314B2 (ja)	2015-02-04	多数のバイオマーカーパネルに基づくうつ障害の診断およびモニタリング
US20120178118A1 (en)	2012-07-12	Biomarkers for monitoring treatment of neuropsychiatric diseases
US20170131295A1 (en)	2017-05-11	Multiple biomarker panels to stratify disease severity and monitor treatment of depression
JP5658571B2 (ja)	2015-01-28	うつ障害をモニタリングするための炎症バイオマーカー
JP5540000B2 (ja)	2014-07-02	うつ病性障害のヒトバイオマーカーハイパーマッピング
CN102301234B (zh)	2015-06-17	针对重度抑郁疾病的代谢综合症状及hpa轴生物标志物
US20170161441A1 (en)	2017-06-08	Methods and materials for treating pain and depression
HK1171081A (en)	2013-03-15	Biomarkers for monitoring treatment of neuropsychiatric diseases
HK1171807A (en)	2013-04-05	Biomarkers for monitoring treatment of neuropsychiatric diseases
HK1190789A (en)	2014-07-11	Biomarkers for monitoring treatment of neuropsychiatric diseases
HK1164379A (en)	2012-09-21	Human biomarker hypermapping for depressive disorders